by The Electrocompetent Cells Market is estimated to be valued at US$ 2.07 Bn in 2023 and is expected to exhibit a CAGR of 10% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
The Electrocompetent Cells Market is an evolving field with continuous innovations paving way for new opportunities. Electrocompetent cells serve as a receptacle to introduce exogenous DNA into bacterial cells through an externally applied electric pulse. They facilitate efficient transformation of plasmid DNA without significant loss in viability of bacterial cells.
Market Overview:
Electrocompetent cells are bacterial cells that can uptake external DNA when exposed to an external electric pulse or field. They find widespread applications in recombinant DNA technology for cloning and gene expression studies. The non-viability and low transformation efficiencies associated with traditional transformation methods are overcome by electrocompetent cells. Their ability to uptake high molecular weight DNA makes them invaluable research tools.
Market key trends:
Increasing R&D spending on cell line development is expected to drive the growth of electrocompetent cells market. Major pharmaceutical and biotech companies are actively investing in cell line development and process optimization for large-scale production of biotherapeutics such as monoclonal antibodies, vaccines, etc. This has propelled the demand for electrocompetent cells for cloning and gene expression applications. Advances in vector design and broader host range are also accelerating the adoption of electrocompetent cells. The development of high-efficiency electrocompetent cells designed for demanding applications involving large plasmids, BACs and cosmids is further fueling the market growth.
Porter’s Analysis
Threat of new entrants: New entrants face high entry barriers as the electrocompetent cells market requires huge investments in R&D to develop efficient cell lines.
Bargaining power of buyers: The bargaining power of buyers is relatively high due to the presence of several established players offering bio-similar products.
Bargaining power of suppliers: A few major players control the supply of raw materials used for producing electrocompetent cells. Thus, the bargaining power of suppliers is moderate to high.
Threat of new substitutes: There exist no close substitutes for electrocompetent cells currently used for various molecular cloning and protein expression applications.
Competitive rivalry: The market experiences high competitive rivalry due to the presence of well-established global players focusing on new product launches and acquisitions.
SWOT Analysis
Strength: Availability of specialized electrocompetent cell lines such as One Shot TOP10, DH5α, and MAX Efficiency Stbl3 enhances the efficiency of molecular cloning.
Weakness: High costs associated with the development and production of advanced cell lines hinders market growth to an extent. Variations in transformation efficiencies limit their extensive use.
Opportunity: Growing R&D expenditure on cell cloning, expression, and engineering by biopharma companies and research institutes presents significant opportunities.
Threats: Stringent regulations pertaining to the development and handling of genetically modified cells pose threats.
Key Takeaways
The global Electrocompetent Cells Market Growth is expected to witness high growth, exhibiting CAGR of 10% over the forecast period, due to increasing R&D investments in pharmaceutical and biotechnology sectors. Regionally, North America dominates the market, followed by Europe. The presence of leading biotech companies and research institutes driving the applications of electrocompetent cells in the two regions. Asia Pacific is expected to exhibit fastest growth during the forecast period, due to setting up of new research facilities and expansion of existing ones.
Key players operating in the electrocompetent cells market are Thermo Fisher Scientific Inc., Merck KGaA, Agilent Technologies, Inc., QIAGEN N.V., Bio-Rad Laboratories, Inc., New England Biolabs, Inc., GenScript Biotech Corporation, Lucigen Corporation, Takara Bio Inc., Delphi Genetics S.A., IBA GmbH, Scarab Genomics LLC, Zymo Research Corporation, and Bioline GmbH (Meridian Bioscience), Cell Applications, Inc.
Regional analysis: North America dominates the electrocompetent cell market with more than 35% share owing to high R&D spending in the region. The Asia Pacific market is expected to grow at the fastest pace during the forecast period with increasing investments in research and development by several key players in countries like China, Japan, and India. Rising research activities focused on molecular cloning and gene
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
